Amesite Inc. (AMST) is a Detroit-based micro-cap software company that develops AI-native clinical documentation tools, principally the NurseMagic® platform and EMR for post-acute and non-acute care, alongside its LynkMagic™ enterprise offering. The stock traded at $0.4898 on Tuesday, down 10.42% from Monday's close of $0.5468, with an intraday low of about $0.4177 in the opening minutes. The direction is unambiguously negative, and the retreat came without any fresh company release, filing, or analyst action. Markets are unwinding a one-day spike built on a new enterprise contract whose financial terms were never quantified.
Monday's 15.12% advance was the catalyst for today's reversal. Turnover that session exceeded 14 million shares against a three-month daily average near 90,000 — an extreme volume expansion for a company with about 6.55 million shares outstanding and a market value of roughly $3.2 million. Moves of that scale in thinly floated micro-caps are frequently driven by momentum participants rather than long-term holders, and the absence of sustained buying pressure on Tuesday is consistent with short-term traders locking in gains from the prior session's surge.
The agreement announced Monday covers a healthcare organization serving approximately 2,000 patients and is expected to expand Amesite's user base and recurring revenue. However, no contract value, term length, or revenue contribution was disclosed. Management framed the deal as part of a broader pattern — a 2,700-census customer in May 2026, a pricing-model win in September 2026, and a homecare connectivity agreement in March 2026 — but investors were left to infer the economics. For a business that generated $364,777 in fiscal 2026 revenue, a single undisclosed contract cannot be reliably modeled, and that uncertainty limits how far the stock can re-rate on the news alone.
Once the headline momentum faded, three verifiable issues returned to the foreground. First, results for the quarter ended September 30, 2026 showed revenue of $70,223 versus $94,296 a year earlier — a decline of roughly 25% — with a net loss of $774,395. Second, Amesite disclosed on November 11 that Nasdaq notified it of non-compliance with the $1.00 minimum bid price rule, giving the company until May 10, 2027 to regain compliance and noting that a reverse stock split is among the options under consideration. Third, the annual report carries substantial-doubt going-concern language and an at-the-market equity program, keeping dilution risk visible. Together these factors make rallies in the name difficult to sustain.
Volume was elevated on an absolute basis but modest relative to Monday, with roughly 50,000 shares changing hands in the first half hour — already more than a typical full session over the past two months. The broader tape offered no help or hindrance: the S&P 500 and Russell 2000 small-cap benchmark were both marginally lower, so the decline was not a sector or index event. Technically, the stock remains well below its 20-day average near $0.56 and its 50-day average around $0.81, keeping the longer downtrend intact despite Monday's bounce. The session's $0.4177 low briefly undercut the $0.46 floor that marked the prior 52-week low area, and the rebound toward $0.49 suggests buyers are defending that zone for now.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news paired with an extreme and rare price move. Amesite earns 40 out of 100. The verified news is moderate in nature — an enterprise contract with undisclosed economics, offset by a revenue decline and a Nasdaq listing deficiency notice — and is not a fundamental transformation for a company of this size. The price move was roughly 3.4 times the stock's average absolute daily change of about 3.1% over the past 70 sessions, and only three sessions in that window produced a comparable or larger swing. Moderate news combined with a moderately unusual move produces the mid-range score.
Attention turns to whether Amesite converts its recent enterprise wins into measurable revenue in the next quarterly report, and whether any of the newly signed agreements carry disclosed dollar values. Investors should also track the company's cash balance against its operating burn, since liquidity and dilution remain central to the equity story. On the listing side, the 180-day compliance window to May 10, 2027 creates a defined timeline for a potential reverse split or a recovery above $1.00. With no sell-side coverage and no published consensus estimates, sentiment will remain headline-driven, and near-term volatility should be expected to stay well above the market average. Key risks include the going-concern disclosure, further equity issuance, and the possibility that momentum fades before the next catalyst.
Tickeron's Trending AI Robots page curates the automated strategies performing best under present market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Each bot differs in strategy logic, holding period, risk profile, and the symbols it trades, so results vary widely across market environments. The Trending section highlights only those currently demonstrating the strongest performance metrics. Explore the page to compare approaches and identify strategies aligned with your own trading horizon and risk tolerance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where AMST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMST's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for AMST just turned positive on November 11, 2026. Looking at past instances where AMST's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMST advanced for three days, in 186 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for AMST entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.271) is normal, around the industry mean (-1.922). P/E Ratio (-0.818) is within average values for comparable stocks, (9.599). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.069) among similar stocks. P/S Ratio (13.280) is also within normal values, averaging (70.699).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. AMST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PackagedSoftware